TAXIS Pharmaceuticals is developing novel antibiotics to address the growing threat of multidrug-resistant bacteria. Our lead product candidate, TXA709, has demonstrated superior in vivo efficacy against methicillin-resistant Staphylococcus aureus (MRSA) and other S. aureus strains resistant to standard-of-care antibiotics, including vancomycin, daptomycin, and linezolid. Based on promising pre-clinical research, TAXIS is preparing to begin clinical studies of TXA709. This rapid progress shows the strength of our drug-discovery capabilities, and signals our transition into a clinical-stage biotechnology company.
TAXIS has the research and development expertise needed for the next phase of the company’s growth. Our researchers have the capability to synthesize new compounds, evaluate their antibacterial and targeting activities, conduct pre-clinical studies, and optimize formulations. Our recently acquired liquid chromatography-mass spectrometry (LCMS) technology enhances our ability to rapidly characterize newly synthesized compounds in real time, significantly enhancing our discovery chemistry throughput.
TAXIS partners with contract manufacturing organizations and contract research organizations to plan and implement clinical development programs. These steps include: initiating Good Manufacturing Practice (GMP) scale-up, maintaining Good Laboratory Practice (GLP), and preparing studies to enable Investigational New Drug (IND) applications for our lead product candidates.